SEARCH

SEARCH BY CITATION

References

  • 1
    Jemal A,Siegel R,Ward E,Murray T,Xu J,Smigal C,Thun MJ. Cancer statistics, 2006. CA Cancer J Clin 2006; 56: 10630.
  • 2
    Chew DK,Attiyeh FF. Experience with the Whipple procedure (pancreaticoduodenectomy) in a university-affiliated community hospital. Am J Surg 1997; 174: 31215.
  • 3
    Ozkan H,Kaya M,Cengiz A. Comparison of tumor marker CA 242 with CA 19-9 and carcinoembryonic antigen (CEA) in pancreatic cancer. Hepatogastroenterology 2003; 50: 166974.
  • 4
    Iacobuzio-Donahue CA,Ashfaq R,Maitra A,Adsay NV,Shen-Ong GL,Berg K,Hollingsworth MA,Cameron JL,Yeo CJ,Kern SE,Goggins M,Hruban RH. Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. Cancer Res 2003; 63: 861422.
  • 5
    Varadarajulu S,Tamhane A,Eloubeidi MA. Yield of EUS-guided FNA of pancreatic masses in the presence or the absence of chronic pancreatitis. Gastrointest Endosc 2005; 62: 72836.
  • 6
    Wakatsuki T,Irisawa A,Bhutani MS,Hikichi T,Shibukawa G,Takagi T,Yamamoto G,Takahashi Y,Yamada Y,Watanabe K,Obara K,Suzuki T, et al. Comparative study of diagnostic value of cytologic sampling by endoscopic ultrasonography-guided fine-needle aspiration and that by endoscopic retrograde pancreatography for the management of pancreatic mass without biliary stricture. J Gastroenterol Hepatol 2005; 20: 170711.
  • 7
    Mallery JS,Centeno BA,Hahn PF,Chang Y,Warshaw AL,Brugge WR. Pancreatic tissue sampling guided by EUS, CT/US, and surgery: a comparison of sensitivity and specificity. Gastrointest Endosc 2002; 56: 21824.
  • 8
    Okai T,Watanabe H,Yamaguchi Y,Mouri I,Motoo Y,Sawabu N. EUS and K-ras analysis of pure pancreatic juice collected via a duodenoscope after secretin stimulation for diagnosis of pancreatic mass lesion: a prospective study. Gastrointest Endosc 1999; 50: 797803.
  • 9
    Harewood GC,Wiersema MJ. Endosonography-guided fine needle aspiration biopsy in the evaluation of pancreatic masses. Am J Gastroenterol 2002; 97: 138691.
    Direct Link:
  • 10
    Takahashi K,Yamao K,Okubo K,Sawaki A,Mizuno N,Ashida R,Koshikawa T,Ueyama Y,Kasugai K,Hase S,Kakumu S. Differential diagnosis of pancreatic cancer and focal pancreatitis by using EUS-guided FNA. Gastrointest Endosc 2005; 61: 769.
  • 11
    Eloubeidi MA,Jhala D,Chhieng DC,Chen VK,Eltoum I,Vickers S,Wilcox CM,Jhala N. Yield of endoscopic ultrasound-guided fine-needle aspiration biopsy in patients with suspected pancreatic carcinoma. Cancer 2003; 99: 28592.
  • 12
    Nakayama T,Morishita T,Kamiya T. K-ras as a genetic marker in pancreatic cancer. Acta Gastroenterol Latinoam 2003; 33: 436.
  • 13
    Niedergethmann M,Rexin M,Hildenbrand R,Knob S,Sturm JW,Richter A,Post S. Prognostic implications of routine, immunohistochemical, and molecular staging in resectable pancreatic adenocarcinoma. Am J Surg Pathol 2002; 26: 157887.
  • 14
    Mu DQ,Peng YS,Xu QJ. Values of mutations of K-ras oncogene at codon 12 in detection of pancreatic cancer: 15-year experience. World J Gastroenterol 2004; 10: 4715.
  • 15
    Uemura K,Hiyama E,Murakami Y,Kanehiro T,Ohge H,Sueda T,Yokoyama T. Comparative analysis of K-ras point mutation, telomerase activity, and p53 overexpression in pancreatic tumours. Oncol Rep 2003; 10: 27783.
  • 16
    Tateishi K,Tada M,Yamagata M,Isayama H,Komatsu Y,Kawabe T,Shiratori Y,Omata M. High proportion of mutant K-ras gene in pancreatic juice of patients with pancreatic cystic lesions. Gut 1999; 45: 73740.
  • 17
    Maitra A,Adsay NV,Argani P,Iacobuzio-Donahue C,De Marzo A,Cameron JL,Yeo CJ,Hruban RH. Multicomponent analysis of the pancreatic adenocarcinoma progression model using a pancreatic intraepithelial neoplasia tissue microarray. Mod Pathol 2003; 16: 90212.
  • 18
    Thayer SP,di Magliano MP,Heiser PW,Nielsen CM,Roberts DJ,Lauwers GY,Qi YP,Gysin S,Fernandez-del Castillo C,Yajnik V,Antoniu B,Warshaw AL, et al. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature 2003; 425: 8516.
  • 19
    Ryu B,Jones J,Blades NJ,Parmigiani G,Hollingsworth MA,Hruban RH,Kern SE. Relationships and differentially expressed genes among pancreatic cancers examined by large-scale serial analysis of gene expression. Cancer Res 2002; 62: 81926.
  • 20
    Logsdon CD,Simeone DM,Binkley C,Arumugam T,Greenson JK,Giordano TJ,Misek DE,Kuick R,Hanash S. Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer. Cancer Res 2003; 63: 264957.
  • 21
    Iacobuzio-Donahue CA,Maitra A,Olsen M,Lowe AW,van Heek NT,Rosty C,Walter K,Sato N,Parker A,Ashfaq R,Jaffee E,Ryu B, et al. Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays. Am J Pathol 2003; 162: 115162.
  • 22
    Friess H,Ding J,Kleeff J,Fenkell L,Rosinski JA,Guweidhi A,Reidhaar-Olson JF,Korc M,Hammer J,Buchler MW. Microarray-based identification of differentially expressed growth- and metastasis-associated genes in pancreatic cancer. Cell Mol Life Sci 2003; 60: 118099.
  • 23
    Seetoo DQ,Crowe PJ,Russell PJ,Yang JL. Quantitative expression of protein markers of plasminogen activation system in prognosis of colorectal cancer. J Surg Oncol 2003; 82: 18493.
  • 24
    Cantero D,Friess H,Deflorin J,Zimmermann A,Brundler MA,Riesle E,Korc M,Buchler MW. Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma. Br J Cancer 1997; 75: 38895.
  • 25
    Han H,Bearss DJ,Browne LW,Calaluce R,Nagle RB,Von Hoff DD. Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray. Cancer Res 2002; 62: 28906.
  • 26
    Paciucci R,Vila MR,Adell T,Diaz VM,Tora M,Nakamura T,Real FX. Activation of the urokinase plasminogen activator/urokinase plasminogen activator receptor system and redistribution of E-cadherin are associated with hepatocyte growth factor-induced motility of pancreas tumor cells overexpressing Met. Am J Pathol 1998; 153: 20112.
  • 27
    Ellenrieder V,Hendler SF,Ruhland C,Boeck W,Adler G,Gress TM. TGF-β-induced invasiveness of pancreatic cancer cells is mediated by matrix metalloproteinase-2 and the urokinase plasminogen activator system. Int J Cancer 2001; 93: 20411.
  • 28
    Swartz MJ,Batra SK,Varshney GC,Hollingsworth MA,Yeo CJ,Cameron JL,Wilentz RE,Hruban RH,Argani P. MUC4 expression increases progressively in pancreatic intraepithelial neoplasia. Am J Clin Pathol 2002; 117: 7916.
  • 29
    Balague C,Audie JP,Porchet N,Real FX. In situ hybridization shows distinct patterns of mucin gene expression in normal, benign, and malignant pancreas tissues. Gastroenterology 1995; 109: 95364.
  • 30
    Saitou M,Goto M,Horinouchi M,Tamada S,Nagata K,Hamada T,Osako M,Takao S,Batra SK,Aikou T, Imai K, Yonezawa S. MUC4 expression is a novel prognostic factor in patients with invasive ductal carcinoma of the pancreas. J Clin Pathol 2005; 58: 84552.
  • 31
    Vercaigne-Marko D,Carrere J,Ducourouble MP,Davril M,Laine A,Amouric M,Figarella C,Hayem A. “In vivo” and “in vitro” inhibition of human pancreatic chymotrypsin A by serum inhibitors. Biol Chem Hoppe Seyler 1987; 368: 3745.
  • 32
    Li Z,Sclabas GM,Peng B,Hess KR,Abbruzzese JL,Evans DB,Chiao PJ. Overexpression of synuclein-γ in pancreatic adenocarcinoma. Cancer 2004; 101: 5865.
  • 33
    Kami K,Doi R,Koizumi M,Toyoda E,Mori T,Ito D,Fujimoto K,Wada M,Miyatake S,Imamura M. Survivin expression is a prognostic marker in pancreatic cancer patients. Surgery 2004; 136: 4438.
  • 34
    Qiao JG,Zhang YQ,Yin YC,Tan Z. Expression of Survivin in pancreatic cancer and its correlation to expression of Bcl-2. World J Gastroenterol 2004; 10: 275961.
  • 35
    Arango D,Wilson AJ,Shi Q,Corner GA,Aranes MJ,Nicholas C,Lesser M,Mariadason JM,Augenlicht LH. Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells. Br J Cancer 2004; 91: 193146.
  • 36
    Kayed H,Kleeff J,Keleg S,Guo J,Ketterer K,Berberat PO,Giese N,Esposito I,Giese T,Buchler MW,Friess H. Indian hedgehog signaling pathway: expression and regulation in pancreatic cancer. Int J Cancer 2004; 110: 66876.
  • 37
    Guweidhi A,Kleeff J,Adwan H,Giese NA,Wente MN,Giese T,Buchler MW,Berger MR,Friess H. Osteonectin influences growth and invasion of pancreatic cancer cells. Ann Surg 2005; 242: 22434.
  • 38
    Binkley CE,Zhang L,Greenson JK,Giordano TJ,Kuick R,Misek D,Hanash S,Logsdon CD,Simeone DM. The molecular basis of pancreatic fibrosis: common stromal gene expression in chronic pancreatitis and pancreatic adenocarcinoma. Pancreas 2004; 29: 25463.
  • 39
    Katoh M. Human FOX gene family (Review). Int J Oncol 2004; 25: 1495500.
  • 40
    Kayed H,Kleeff J,Kolb A,Ketterer K,Keleg S,Felix K,Giese T,Penzel R,Zentgraf H,Buchler MW,Korc M,Friess H. FXYD3 is overexpressed in pancreatic ductal adenocarcinoma and influences pancreatic cancer cell growth. Int J Cancer 2005; 118: 4354.
  • 41
    Matheus CJ,Rendell LA. Constructive induction on decision trees, in Proceedings of the 11th International Joint Conference on Artificial Intelligence, 1989, Detroit, MI (USA).
  • 42
    Blasi F,Carmeliet P. uPAR: A versatile signalling orchestrator. Nat Rev Mol Cell Biol 2002; 3: 93243.
  • 43
    Bagheri-Yarmand R,Mazumdar A,Sahin AA,Kumar R. LIM kinase 1 increases tumor metastasis of human breast cancer cells via regulation of the urokinase-type plasminogen activator system. Int J Cancer 2006; 118: 270310.
  • 44
    Nozaki S,Endo Y,Nakahara H,Yoshizawa K,Hashiba Y,Kawashiri S,Tanaka A,Nakagawa K,Matsuoka Y,Kogo M,Yamamoto E. Inhibition of invasion and metastasis in oral cancer by targeting urokinase-type plasminogen activator receptor. Oral Oncol 2005; 41: 9717.
  • 45
    Li P,Gao Y,Ji Z,Zhang X,Xu Q,Li G,Guo Z,Zheng B,Guo X. Role of urokinase plasminogen activator and its receptor in metastasis and invasion of neuroblastoma. J Pediatr Surg 2004; 39: 151219.
  • 46
    Trisciuoglio D,Iervolino A,Candiloro A,Fibbi G,Fanciulli M,Zangemeister-Wittke U,Zupi G,Del Bufalo D. bcl-2 induction of urokinase plasminogen activator receptor expression in human cancer cells through Sp1 activation: involvement of ERK1/ERK2 activity. J Biol Chem 2004; 279: 673745.
  • 47
    Bauer TW,Liu W,Fan F,Camp ER,Yang A,Somcio RJ,Bucana CD,Callahan J,Parry GC,Evans DB,Boyd DD,Mazar AP, et al. Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice. Cancer Res 2005; 65: 777581.
  • 48
    Ohtani H,Pyke C,Dano K,Nagura H. Expression of urokinase receptor in various stromal-cell populations in human colon cancer: immunoelectron microscopical analysis. Int J Cancer 1995; 62: 6916.
  • 49
    Dasgupta S,Tripathi PK,Qin H,Bhattacharya-Chatterjee M,Valentino J,Chatterjee SK. Identification of molecular targets for immunotherapy of patients with head and neck squamous cell carcinoma. Oral Oncol 2006; 42: 30616.
  • 50
    Ohmachi T,Tanaka F,Mimori K,Inoue H,Yanaga K,Mori M. Clinical significance of TROP2 expression in colorectal cancer. Clin Cancer Res 2006; 12: 305763.
  • 51
    Jantscheff P,Terracciano L,Lowy A,Glatz-Krieger K,Grunert F,Micheel B,Brummer J,Laffer U,Metzger U,Herrmann R,Rochlitz C. Expression of CEACAM6 in resectable colorectal cancer: a factor of independent prognostic significance. J Clin Oncol 2003; 21: 363846.
  • 52
    Blumenthal RD,Hansen HJ,Goldenberg DM. Inhibition of adhesion, invasion, and metastasis by antibodies targeting CEACAM6 (NCA-90) and CEACAM5 (Carcinoembryonic Antigen). Cancer Res 2005; 65: 880917.
  • 53
    Duxbury MS,Matros E,Clancy T,Bailey G,Doff M,Zinner MJ,Ashley SW,Maitra A,Redston M,Whang EE. CEACAM6 is a novel biomarker in pancreatic adenocarcinoma and PanIN lesions. Ann Surg 2005; 241: 4916.
  • 54
    Haraguchi N,Utsunomiya T,Inoue H,Tanaka F,Mimori K,Barnard GF,Mori M. Characterization of a side population of cancer cells from human gastrointestinal system. Stem Cells 2006; 24: 50613.
  • 55
    Tomita M,Matsuzaki Y,Shimizu T,Hara M,Ayabe T,Onitsuka T. Prognostic determinants for lung cancer patients with preoperative high serum carcinoembryonic antigen levels. Thorac Cardiovasc Surg 2005; 53: 3004.
  • 56
    Ring BZ,Seitz RS,Beck R,Shasteen WJ,Tarr SM,Cheang MC,Yoder BJ,Budd GT,Nielsen TO,Hicks DG,Estopinal NC,Ross DT. Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast cancer. J Clin Oncol 2006; 24: 303947.